Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Arcus Biosciences, Inc. (RCUS : NYSE)
 
 • Company Description   
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.

Number of Employees: 366

 
 • Price / Volume Information   
Yesterday's Closing Price: $18.92 Daily Weekly Monthly
20 Day Moving Average: 1,587,428 shares
Shares Outstanding: 71.72 (millions)
Market Capitalization: $1,356.92 (millions)
Beta: 1.00
52 Week High: $49.10
52 Week Low: $16.74
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -30.95% -24.39%
12 Week -48.16% -41.74%
Year To Date -53.25% -42.89%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3928 Point Eden Way
-
Hayward,CA 94545
USA
ph: 510-694-6200
fax: -
investorinfo@arcusbio.com http://www.arcusbio.com
 
 • General Corporate Information   
Officers
Terry Rosen - Chief Executive Officer and Director
Juan Carlos Jaen - President and Director
Jennifer Jarrett - Chief Operating Officer and Director
Robert C. Goeltz - Chief Financial Officer
Kathryn Falberg - Director

Peer Information
Arcus Biosciences, Inc. (CORR.)
Arcus Biosciences, Inc. (RSPI)
Arcus Biosciences, Inc. (CGXP)
Arcus Biosciences, Inc. (BGEN)
Arcus Biosciences, Inc. (GTBP)
Arcus Biosciences, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03969F109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 71.72
Most Recent Split Date: (:1)
Beta: 1.00
Market Capitalization: $1,356.92 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.93 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.03 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: 34.40
PEG Ratio: -
Price Ratios
Price/Book: 1.70
Price/Cash Flow: 21.63
Price / Sales: 3.47
EPS Growth
vs. Year Ago Period: 11.11%
vs. Previous Quarter: -125.88%
Sales Growth
vs. Year Ago Period: 90.31%
vs. Previous Quarter: -94.92%
ROE
03/31/22 - 8.25
12/31/21 - 7.96
09/30/21 - -48.12
ROA
03/31/22 - 4.71
12/31/21 - 4.95
09/30/21 - -32.32
Current Ratio
03/31/22 - 7.84
12/31/21 - 7.60
09/30/21 - 3.82
Quick Ratio
03/31/22 - 7.84
12/31/21 - 7.60
09/30/21 - 3.82
Operating Margin
03/31/22 - 14.67
12/31/21 - 13.80
09/30/21 - -735.12
Net Margin
03/31/22 - 14.67
12/31/21 - 13.80
09/30/21 - -735.12
Pre-Tax Margin
03/31/22 - 15.39
12/31/21 - 14.27
09/30/21 - -735.12
Book Value
03/31/22 - 11.11
12/31/21 - 11.98
09/30/21 - 7.72
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©